首页 | 本学科首页   官方微博 | 高级检索  
     


Serum ghrelin concentrations in patients receiving olanzapine or risperidone
Authors:Takashi Togo  Koichi Hasegawa  Satoshi Miura  Hideki Hosojima  Katsuo Kojima  Mika Shoji  Akihiko Kase  Hirotake Uchikado  Eizo Iseki  Kenji Kosaka
Affiliation:(1) Department of Psychiatry, Yokohama Maioka Hospital, Maioka-cho 3482, Totsuka-ku, 244-0813 Yokohama, Japan;(2) Department of Psychiatry, Yokohama City University School of Medicine, Yokohama, Japan;(3) Radioisotope Research Center, Yokohama City University School of Medicine, Yokohama, Japan
Abstract:Rationale Although enhanced appetite and weight gain are potential side effects of treatment with antipsychotic agents, particularly olanzapine and clozapine, the mechanism is poorly understood.Objectives To test the hypothesis that ghrelin, a gastrointestinal hormone that enhances appetite, is involved in increased food intake and weight gain during treatment with antipsychotics.Methods Serum ghrelin concentrations were investigated in schizophrenic patients receiving olanzapine or risperidone, and in healthy volunteers.Results Serum ghrelin concentrations did not increase, but rather decreased, in patients treated with olanzapine or risperidone in comparison with healthy volunteers. No significant difference was found in serum ghrelin concentration between patients treated with olanzapine and risperidone.Conclusions Our results indicate that ghrelin is not a direct cause of increased food intake and weight gain during treatment with olanzapine or risperidone, whereas ghrelin is associated with metabolic change in patients receiving these agents.
Keywords:Ghrelin  Olanzapine  Risperidone  Appetite  Weight gain
本文献已被 PubMed SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号